Galderma R&D
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Galderma R&D sits in the top decile of US sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count).
Galderma R&D: 158 sponsored US clinical trials, 7 recruiting.
Galderma R&D sponsors 158 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 142 completed. 90 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 7 trials.
Top-decile sponsor footprint
Galderma R&D ranks in the top decile of sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
142 of 146 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (97.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
158 total, page 2 of 4
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Platysmal Bands
NCT04080882
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT03989349
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
NCT03985943
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03960957
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
NCT03921411
Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris
NCT03915860
Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.
NCT03780244
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03736928
GAL1704 for Cheek Augmentation and Correction of Midface Contour Deficiencies
NCT03700047
Subject Satisfaction With AbobutulinumtoxinA Treatment
NCT03687736
A Study to Evaluate the Safety and Efficacy of Restylane Defyne for Chin Augmentation and Correction of Chin Retrusion
NCT03624816
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
NCT03292406
New Dermal Filler for Lip Augmentation
NCT03320824
Oracea Soolantra Association in Participants With Severe Rosacea
NCT03075891
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
NCT03100344
Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation
NCT03160716
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
NCT02932267
A Treatment for Severe Inflammatory Acne Subjects
NCT02899000
A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments
NCT02755545
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
NCT02718118
Injection Technique Assessment of Restylane Silk With Lidocaine for Lip Augmentation
NCT02703948
MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
NCT02616250
Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand
NCT02650921
Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
NCT02566369
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
NCT02556788
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
NCT02460497
Sculptra Aesthetic Post-Approval Study
NCT02425943
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia
NCT02460289
CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
NCT02189629
Mirvaso in Use Study
NCT02249065
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
NCT02236312
A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris
NCT02249104
Plaque Psoriasis Study in Pediatric Subjects
NCT02186665
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
NCT02125279
Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris
NCT01951417
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
NCT01893567
Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris
NCT01880320
Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.
NCT01909713
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
NCT01872715
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
NCT01766440
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser
NCT01888887
Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash
NCT01892410
Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50
NCT01887860
Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis
NCT01753830
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
NCT01659853
Dose Range Study of CD5789 in Acne Vulgaris
NCT01616654
Anesthetic Effect Duration Assessment
NCT01545765
Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel
NCT01522456
Phase 3 Papulopustular Rosacea Study
NCT01494467
Phase 3 Papulopustular Rosacea Study
NCT01493687
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 24 |
| Phase 3 | 41 |
| Phase 4 | 49 |
Therapeutic Areas
Where Galderma R&D enrollment is open (later-stage tilt)
7 recruiting of 158 indexed (4% open); 142 completed (90%).
Phase mix: 90 late (III/IV) vs 28 early (I/II) (later-stage heavy).
Top condition: Acne Vulgaris (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Galderma R&D: open-pipeline peers nationwide
Peers matched on 158 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Galderma R&D sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 158 trials (± recruiting share)
- Pfizer's Upjohn has merged with Mylan to form Viatris · 158 trials · 0% recruiting
- Ann & Robert H Lurie Children's Hospital of Chicago · 159 trials · 19% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Alexion Pharmaceuticals · 162 trials · 10% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 4% recruiting · 45 trials
- Craig L Slingluff, Jr · 4% recruiting · 23 trials
- Esperion Therapeutics · 4% recruiting · 23 trials
- Tonix Pharmaceuticals · 4% recruiting · 23 trials
Related
What to do with this Galderma R&D page
158 registered trials is a research-attention snapshot, not an endorsement of Galderma R&D or any single study.
- 7 of Galderma R&D's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acne Vulgaris is the condition Galderma R&D studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Galderma R&D pipeline card: 158 registered trials from official public datasets.Report a data error.